Rachel Thijssen Selected Research

Phosphotransferases (Kinase)

8/2015

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rachel Thijssen Research Topics

Disease

9	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2023 - 08/2015
6	Neoplasms (Cancer) 06/2023 - 01/2019
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 01/2019
2	Hematologic Neoplasms (Hematological Malignancy) 06/2023 - 01/2021
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2023 - 01/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 11/2020
1	Breast Neoplasms (Breast Cancer) 06/2023
1	Leukemia 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Disease Progression 01/2019
1	Lymphocytosis 01/2016
1	Lymphadenopathy 01/2016

Drug/Important Bio-Agent (IBA)

12	venetoclaxIBA 06/2023 - 08/2015
4	Proteins (Proteins, Gene)FDA Link 11/2022 - 10/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2016
1	EpitopesIBA 06/2023
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	navitoclaxIBA 01/2021
1	Circulating Tumor DNAIBA 01/2019
1	ibrutinibIBA 01/2019
1	1- ethyl- 7- (2- methyl- 6- (1H- 1,2,4- triazol- 3- yl)pyridin- 3- yl)- 3,4- dihydropyrazino(2,3- b)pyrazin- 2(1H)- oneIBA 01/2016
1	Phosphotransferases (Kinase)IBA 08/2015
1	AntibodiesIBA 08/2015

Therapy/Procedure

5	Therapeutics 11/2022 - 01/2019
1	Immunotherapy 06/2023